Management of Hepatitis C Infection with Direct Action Antiviral Drugs (DAA)**
Journal Title: Archives of Hepatitis Research - Year 2015, Vol 1, Issue 1
Abstract
Several new direct action antiviral drugs (DAA) against the HCV virus (HCV) are approved and marketed. The combination of DAA with pegylated interferon and ribavirin (PR) is only recommended to patients with tolerance to interferon (IFN). IFN-free treatments are now considered elective drugs for patients with chronic HCV. More than 90% of patients infected with HCV genotype 1 or 4 (fewer with other genotypes) show sustained virological response, when treated with sofosbuvir combined with simeprevir, daclatasvir or ledipasvir, or by the combination of paritaprevir with ritonavir, ombitasvir and dasabuvir, with or without ribavirin.
Authors and Affiliations
Focaccia Roberto, de Mello Rodolfo Ferreira, Montes Patrícia Silva, Conti Flávio Martin
Keywords
Related Articles
- EP ID EP558574
- DOI 10.17352/ahr.000003
- Views 33
- Downloads 0
The correlation between serum cytokine levels and liver cirrhosis in chronic hepatitis B patients: A meta-analysis
Background: The harm of liver cirrhosis (LC) is serious, and the development of LC is primarily resulted from chronic hepatitis B virus (HBV) in high-risk such as China and Africa and chronic hepatitis C virus (HCV) in d...
The Potential of Liver Fibrosis Indexes/Scores for the Screening of Cryptic Liver Fibrosis in Patients with NASH Risk Factors: A Case Report
The unintentional discovery of cirrhosis in a patient with prostate cancer lead us to enquire if some of the indexes/scored designed for the evaluation of liver fibrosis/cirrhosis, in Chronic Hepatitis C patients, could...
Management of Hepatitis C Infection with Direct Action Antiviral Drugs (DAA)**
Several new direct action antiviral drugs (DAA) against the HCV virus (HCV) are approved and marketed. The combination of DAA with pegylated interferon and ribavirin (PR) is only recommended to patients with tolerance to...
Farnesoid X Receptor Agonist as a new treatment option for Non-Alcoholic Fatty Liver disease: A Review
Background: Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of fatty liver, characterized by the accumulation of fat in the hepatocytes in the absence of alcohol consumption. The spectrum of th...
Accidentally discovered Portal Vein Thrombosis before Splenectomy due to Hypersplenism - The role of Thrombogenic Genes Polymorphisms
Portal vein thrombosis in patients with liver cirrhosis may be due neoplastic growth invading portal vein or due to non-neoplastic causes. The indications for treating PVT in cirrhotic individuals are difficult to be est...